Lataa...
Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
This randomized withdrawal study assessed relapse prevention with vilazodone in adults with major depressive disorder. After 20 weeks of open-label treatment with vilazodone 40 mg/day, responders were randomized (1 : 1 : 1) to 28 weeks of double-blind, fixed-dose treatment with vilazodone 20 mg/day,...
Tallennettuna:
| Julkaisussa: | Int Clin Psychopharmacol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Lippincott Williams And Wilkins
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166708/ https://ncbi.nlm.nih.gov/pubmed/30044247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000236 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|